Nerves Inhibit Melanoma Growth
Analysis based on 6 articles · First reported Apr 29, 2026 · Last updated Apr 30, 2026
This medical breakthrough by Weill Cornell Medicine could significantly impact the biotechnology and pharmaceutical industries by opening new avenues for anti-cancer therapies. Companies developing drugs targeting adrenergic receptors or sympathetic nerves may see increased investor interest and potential for new product development.
A study led by Weill Cornell Medicine investigators, including David J. Simon and Tingting Liu, discovered that sympathetic nerve fibers within melanomas can inhibit tumor growth. This finding challenges previous assumptions that the nervous system primarily drives cancer growth. The research, published in Neuron, indicates that sympathetic nerves release norepinephrine, which activates alpha adrenergic receptors on macrophages, thereby reducing the number of pro-tumor macrophages and slowing melanoma progression. This breakthrough, supported by entities like the United States — National Cancer Institute, United States — National Institutes of Health, United States — United States Department of Defense, Pershing Square Sohn Cancer Research Alliance, and Walton Family Foundation, suggests potential for new anti-cancer therapies, possibly utilizing existing blood pressure medications that target these receptors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard